Fiche société
ProgenaBiome
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications3liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Fecal Microbiota TransplantFMT may significantly improve quality of life and Parkinson Disease (PD) symptom severity measurements. We hypothesize that gut microbial dysbiosis is a major contributing factor in Parkinson's disease. | Parkinson | Phase 1 | Traitement symptomatique | United States | À vérifier |
| Fecal Microbiota TransplantFMT may significantly improve quality of life and Parkinson Disease (PD) symptom severity measurements. We hypothesize that gut microbial dysbiosis is a major contributing factor in Parkinson's disease. | Parkinson | Phase 1 | Traitement symptomatique | United States | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Fecal Microbiota Transplant | Parkinson | Phase 1 | NCT06647277 | Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease | NOT_YET_RECRUITING |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Fecal Microbiota Transplant | The Trajectory of Gastrointestinal Symptom Experience Following Fecal Microbiota Transplant for Recurrent Clostridioides Difficile Infection. | Journal of clinical gastroenterology | ||
| Fecal Microbiota Transplant | Therapeutic modulation of the gut-brain axis in alcohol use disorder: A systematic review. | Metabolism open | ||
| Fecal Microbiota Transplant | Alcohol consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): understanding the gut-liver crosstalk for clinical translation. | Gut microbes |